Historical brief · 2026-11-16

Helus' Psychedelic Depression Drug Succeeds in Phase 3 Trial But Faces Safety Scrutiny

According to Helus Pharma, its psychedelic drug candidate HLP003 significantly reduced major depression symptoms in a Phase 3 clinical trial. However, the study also recorded a number of serious adverse events, casting doubt on the overall safety of the treatment.

Source image · STAT Biotech

Helus Pharma announced that its psychedelic drug candidate, HLP003, showed positive results in a Phase 3 clinical trial for major depression. In the study, participants received one dose on the first day and a second dose three weeks later alongside standard antidepressants. At six weeks, the treatment group achieved a 19.5-point reduction on the MADRS depression rating scale, compared to an 11.9-point reduction in the placebo group. At 12 weeks, the effect was largely sustained, with a 16.9-point reduction for the treatment group versus 9.9 points for the placebo group, with all differences being statistically significant.

Despite the promising efficacy data, the trial recorded a number of serious adverse events. These safety concerns have raised questions regarding the risk-benefit profile of utilizing psychedelics for psychiatric conditions, a therapeutic avenue currently being explored by multiple companies in the biotechnology sector.

View selection rationale
Media reportStage not established

Importance 73/100

Signal70Structure75Consequence75Confidence75Momentum65
About this brief
Content type
News summary
Source type
Publisher report
Original source
STAT Biotech ↗
Source published
Process
AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
Verification
The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
Published by
Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
Conflict disclosure
No financial or commercial conflict declared.

Editorial standards → · Corrections →

POLYEMERGENCE / EXPLORE

Keep exploring

Follow the topic, not just the headline.

Explore the Biotech & Programmable Life archive →